Chemocentryx (CCXI) Reports Q4 EPS of 61c, Revs Double

Chemocentryx (NASDAQ: CCXI) reported Q4 EPS of $0.61, versus $0.17 reported last year. Revenue for the quarter came in at $26.1 thousand, versus $13.1 million reported last year.

For earnings history and earnings-related data on Chemocentryx (CCXI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
• Vista Outdoor (VSTO) CSG Sends Letter to Senator J.D. Vance Addressing His Concerns Regarding Planned Acquisition of Vista Outdoor’s Sporting Products Business (VSTO)
• Barrick Gold (GOLD) reported preliminary Q1 production of 940 thousand ounces of gold